Key result
Dabigatran, a direct thrombin inhibitor, is being explored for its potential role in the long-term management of patients with acute coronary syndrome to overcome the limitations of warfarin.
Dabigatran is being explored as a potential alternative to warfarin for long-term anticoagulation in patients with coronary artery disease and acute coronary syndrome.
Dabigatran remains investigational for long-term ACS anticoagulation; leaves open the need for RCTs versus warfarin.
The pharmacologic management of patients with high-risk coronary artery disease consists of aspirin and a P2Y12 receptor inhibitor. Chronic oral anticoagulation with warfarin is the major treatment strategy to attenuate thromboembolism or stroke in patients with deep vein thrombosis, pulmonary embolism, heart failure and atrial fibrillation. A substantial percentage of the latter group of patients have coronary artery disease and may require stenting with long-term dual antiplatelet therapy in addition to therapy with warfarin to reduce arterial ischemic events in addition to stroke. These new oral anticoagulants have been developed for long-term therapy to overcome the limitations of warfarin. Dabigatran is a direct thrombin inhibitor and its role in patients with acute coronary syndrome is being explored.
No takes yet. Share an insight, caveat, or question.
Doraiswamy et al. (2013) conducted a review in Coronary artery disease. Dabigatran vs. Warfarin was evaluated. Dabigatran, a direct thrombin inhibitor, is being explored for its potential role in the long-term management of patients with acute coronary syndrome to overcome the limitations of warfarin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: